Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$502K Sell
3,906
-19
-0.5% -$2.22K 0.16% 79
2026
Q1
$472K Hold
3,925
0.16% 79
2025
Q4
$413K Hold
3,925
0.14% 81
2025
Q3
$329K Hold
3,925
0.11% 85
2025
Q2
$311K Hold
3,925
0.11% 87
2025
Q1
$352K Hold
3,925
0.13% 82
2024
Q4
$390K Hold
3,925
0.14% 80
2024
Q3
$446K Sell
3,925
-120
-3% -$14.3K 0.16% 76
2024
Q2
$501K Hold
4,045
0.18% 75
2024
Q1
$534K Hold
4,045
0.2% 72
2023
Q4
$441K Hold
4,045
0.18% 73
2023
Q3
$416K Hold
4,045
0.18% 74
2023
Q2
$467K Hold
4,045
0.19% 73
2023
Q1
$430K Hold
4,045
0.19% 72
2022
Q4
$449K Sell
4,045
-65
-2% -$6.64K 0.2% 72
2022
Q3
$354K Buy
+4,110
New +$367K 0.17% 79
2022
Q2
Sell
-3,085
Closed -$253K 126
2022
Q1
$253K Sell
3,085
-475
-13% -$37.5K 0.1% 98
2021
Q4
$273K Buy
+3,560
New +$284K 0.1% 94
2020
Q1
Sell
-2,625
Closed -$228K 92
2019
Q4
$228K Hold
2,625
0.13% 89
2019
Q3
$211K Hold
2,625
0.13% 93
2019
Q2
$203K Hold
2,625
0.13% 94
2019
Q1
$208K Buy
+2,625
New +$196K 0.14% 86

Other funds holding MRK

Oak Asset Management's MRK Position: Q2 2026 in Review

Oak Asset Management reduced its Merck (MRK) stake by 0.48% in Q2 2026, selling an estimated $2.22K and leaving 3,906 shares worth $502K. The position accounts for 0.16% of the portfolio, ranked #79.

Oak Asset Management first reported a position in MRK in Q1 2019 and has held it in 22 quarters since. The position peaked at $534K in Q1 2024. 925 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Oak Asset Management held 3,906 shares of Merck worth $502K as of Q2 2026.
  • Oak Asset Management sold 19 Merck shares in Q2 2026, an estimated $2.22K.
  • Merck made up 0.16% of Oak Asset Management's portfolio in Q2 2026, its #79 holding.
  • Oak Asset Management first reported a position in Merck in Q1 2019 and has held it in 22 quarters since.
  • Oak Asset Management's Merck position peaked at $534K in Q1 2024.
  • 925 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Oak Asset Management's 13F filing for Q2 2026, filed 13 Jul 2026.